Patients suffering from drug refractory recurrent symptomatic paroxysmal atrial fibrillation have a new therapeutic option, and it is a minimally invasive one.The FDA awarded J&J’s Biosense Webster marketing approval for the NAVISTAR® THERMOCOOL® ablation system, a device designed to perform afib ablations by electrophysiologists in cath labs. The system is officially indicated “for the treatment of Type 1 atrial flutter, and recurrent drug/device refractory sustained monomorphic ventricular tachycardia due to prior myocardial infarction”.
Some benefits of the system from the product brochure:
The ThermoCool® Catheter is the first power controlled, open-loop irrigated catheter. It is designed to maintain lower tip-to-tissue temperatures so you can deliver the power you need. This provides a range of significant benefits:
Reduces char and thrombus formation. Allows you to apply the power needed to create a wider variety of lesion types and effectively monitor
catheter tip cooling.
Active cooling permits delivery of constant, preset energy regardless of local blood flow cooling. Controlled flow of cooling saline is designed to maintain safe tip-to-tissue temperature. May reduce the number of RF applications needed. Designed to provide shorter procedure times and reduced fluoroscopy.
Here’s an entire ablation video course on how to use Biosense Webster’s system:
Product page: THERMOCOOL Irrigated Tip Catheter and Integrated Ablation System
Press release: FDA Grants Marketing Approval to NAVISTAR(R) THERMOCOOL(R) Catheter for Atrial Fibrillation